HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celularity (NASDAQ:CELU) with a Buy and lowers the price target from $15 to $2.5.
EXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes Candidate
SAB Biotherapeutics (NASDAQ: SABS) has entered into a securities purchase agreement with certain investors to issue and sell shares of preferred stock in a private placement of up to $130 million in gross proceeds.
